YL Pharma’s Licence Cancelled for Defying Drug Manufacturing Ban
The Drugs Control Administration (DCA) of Himachal has cancelled the manufacturing license of a famous pharma company called YL Pharma. YL Pharma’s licence was cancelled due to violations. This company is located in Katha Village, Baddi. The reason for taking this action is that the company was producing drugs even after they were banned by the government.
The Company has violated the Drugs and Cosmetics Act, 1940. This was identified by the authorities, and the government had given an order in March 2025 asking the company to stop its manufacturing. But they did not respect it, rather disregarded it and continued their production illegally.
To take action for the mistake and for a proper response, the authorities issued a notice on November 3rd. But even after that, the company did not respond properly and this led to YL Pharma’s Licence Cancellation immediately.
There was an inspection that was conducted at the company in March. The authorities seized 135 empty strips of Pregabalin capsules. The packaging had the name of a firm based in Sikkim, and this was an attempt by them to misbrand and dodge rules. YL Pharma’s Licence Cancelled for the very same reason.
The state drugs controller, Dr. Manish Kapoor, gives a confirmation that all the manufacturing permissions of YL Pharma’s license have been taken away as the company repeatedly disregarded regulatory rules. The officials also mentioned that they will lead further legal proceedings after the full investigations are over.
The action came after the Rajasthan Drugs Control Administration alerted authorities that a batch of Levocetirizine tablets (Wincet-L) made by YL Pharma had no active ingredient, making the medicine fake and of poor quality.
Baddi is one of the major pharmaceutical zones and is also one of the largest pharma hubs of the country. This incident has brought attention and focus towards illegal and poor quality manufacturing practices. Regulatory officials say that this breaks the trust of the public and also most importantly, will lead to serious health risks.
This incident has now brought the need for stricter compliance checks and regulations. The manufacturers should also be more accountable for the same. This way, we will be able to protect the integrity of India’s pharma sector and gain more trust from the public.
